These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 17255158)

  • 1. Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides.
    Ueda Y; Shimizu K; Itoh T; Fuji N; Naito K; Shiozaki A; Yamamoto Y; Shimizu T; Iwamoto A; Tamai H; Yamagishi H
    Jpn J Clin Oncol; 2007 Feb; 37(2):140-5. PubMed ID: 17255158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide.
    Nishiyama T; Tachibana M; Horiguchi Y; Nakamura K; Ikeda Y; Takesako K; Murai M
    Clin Cancer Res; 2001 Jan; 7(1):23-31. PubMed ID: 11205913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
    Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D
    Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
    Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IFN-gamma responses in peptide-treated melanoma patients measured by an ELISPOT assay using allogeneic dendritic cells.
    Gabrielsson S; Brichard V; Dhellin O; Dorval T; Bonnerot C
    Anticancer Res; 2004; 24(1):171-7. PubMed ID: 15015594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of recurrent malignant melanoma of esophagus responsive to combined chemotherapy, radiotherapy and cellular immunotherapy].
    Motoyama S; Maruyama K; Sato Y; Shibuya K; Usami S; Yoshino K; Nakatsu T; Nanjo H; Kamata S; Ogawa J
    Gan To Kagaku Ryoho; 2011 Apr; 38(4):639-42. PubMed ID: 21498995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
    Lesimple T; Neidhard EM; Vignard V; Lefeuvre C; Adamski H; Labarrière N; Carsin A; Monnier D; Collet B; Clapisson G; Birebent B; Philip I; Toujas L; Chokri M; Quillien V
    Clin Cancer Res; 2006 Dec; 12(24):7380-8. PubMed ID: 17189411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
    Davis ID; Chen Q; Morris L; Quirk J; Stanley M; Tavarnesi ML; Parente P; Cavicchiolo T; Hopkins W; Jackson H; Dimopoulos N; Tai TY; MacGregor D; Browning J; Svobodova S; Caron D; Maraskovsky E; Old LJ; Chen W; Cebon J
    J Immunother; 2006; 29(5):499-511. PubMed ID: 16971806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas.
    Sadanaga N; Nagashima H; Mashino K; Tahara K; Yamaguchi H; Ohta M; Fujie T; Tanaka F; Inoue H; Takesako K; Akiyoshi T; Mori M
    Clin Cancer Res; 2001 Aug; 7(8):2277-84. PubMed ID: 11489802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined immunocell therapy using activated lymphocytes and monocyte-derived dendritic cells for malignant melanoma.
    Goto S; Kaneko T; Miyamoto Y; Eriguchi M; Kato A; Akeyama T; Fujimoto K; Tomonaga M; Egawa K
    Anticancer Res; 2005; 25(6A):3741-6. PubMed ID: 16302734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential role of dendritic cell vaccination with MAGE peptides in gastrointestinal carcinomas.
    Tanaka F; Haraguchi N; Isikawa K; Inoue H; Mori M
    Oncol Rep; 2008 Nov; 20(5):1111-6. PubMed ID: 18949409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility study of adoptive immunotherapy for metastatic lung tumors using peptide-pulsed dendritic cell-activated killer (PDAK) cells.
    Yamaguchi Y; Ohta K; Kawabuchi Y; Ohshita A; Okita R; Okawaki M; Hironaka K; Matsuura K; Toge T
    Anticancer Res; 2005; 25(3c):2407-15. PubMed ID: 16080467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro.
    Vujanovic L; Ranieri E; Gambotto A; Olson WC; Kirkwood JM; Storkus WJ
    Cancer Gene Ther; 2006 Aug; 13(8):798-805. PubMed ID: 16645618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune characterization of clinical grade-dendritic cells generated from cancer patients and genetically modified by an ALVAC vector carrying MAGE minigenes.
    Trakatelli M; Toungouz M; Lambermont M; Heenen M; Velu T; Bruyns C
    Cancer Gene Ther; 2005 Jun; 12(6):552-9. PubMed ID: 15665821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
    J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rhabdomyosarcomas are potential target of MAGE-specific immunotherapies.
    Tanzarella S; Lionello I; Valentinis B; Russo V; Lollini PL; Traversari C
    Cancer Immunol Immunother; 2004 Jun; 53(6):519-24. PubMed ID: 14727086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.
    Butterfield LH; Ribas A; Dissette VB; Amarnani SN; Vu HT; Oseguera D; Wang HJ; Elashoff RM; McBride WH; Mukherji B; Cochran AJ; Glaspy JA; Economou JS
    Clin Cancer Res; 2003 Mar; 9(3):998-1008. PubMed ID: 12631598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
    J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
    Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
    J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.